TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice
Clicks: 197
ID: 110005
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
197 views
21 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #60 of 213 articles by views in endocrinology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 213 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract. TBR-760 (formerly BIM-23A760) is a chimeric dopamine (DA)-somatostatin (SST) compound with potent agonist activity at both DA type 2 (D2R) and SST ty
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (26 words).
Try re-searching for a better abstract.
| Reference Key |
a2020endocrinologytbr-760,
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Halem, Heather A;Hochgeschwender, Ute;Rih, Jeong Keun;Nelson, Richard;Johnson, G Allan;Thiagalingam, Arunthi;Culler, Michael D; |
| Journal | endocrinology |
| Year | 2020 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.